VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

chikungunya virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Introduction
  2. Vaccine Information
    1. MVA-CHIKV
  3. References
I. General Information
1. NCBI Taxonomy ID:
37124
2. Introduction
The emerging chikungunya virus (CHIKV) causes a severe disease in humans (García-Arriaza et al., 2014).
II. Vaccine Information
1. MVA-CHIKV
a. Vaccine Ontology ID:
VO_0004666
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
The highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA) was used to express the CHIKV C, E3, E2, 6K, and E1 structural genes (termed MVA-CHIKV) (García-Arriaza et al., 2014).
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
III. References
1. García-Arriaza et al., 2014: García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. Journal of virology. 2014; 88(6); 3527-3547. [PubMed: 24403588].